Physician profile
Igor Priven
NPI 1518938422
$2,854.29
in general payments reported to CMS, 2019-2025
31 companies · $217 in 2025
The $217 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $761 · 2020: $548 · 2021: $409 · 2022: $340 · 2023: $203 · 2024: $375 · 2025: $217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $795.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $795.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $512.39 | 2019-2025 | Repatha, Evenity, Prolia |
| Novo Nordisk INC | $362.63 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $273.81 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $256.24 | 2019-2025 | Jardiance |
| Abbvie INC. | $212.98 | 2019-2022 | |
| Lilly USA, LLC | $133.92 | 2019-2025 | Jardiance, Mounjaro |
| Janssen Pharmaceuticals, INC | $119.69 | 2019 | |
| Abbott Laboratories | $117.82 | 2021-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $116.34 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $114.84 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $112.65 | 2019-2021 | |
| Corcept Therapeutics | $59.70 | 2024 | Korlym |
| Radius Health, INC. | $59.66 | 2019-2023 | Tymlos |
| Sanofi-Aventis U.S. LLC | $43.36 | 2019-2021 | |
| Mannkind Corporation | $43.00 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optos, INC. | $38.34 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.50 | 2022-2024 | |
| Pfizer INC. | $27.63 | 2019-2023 | |
| Amarin Pharma, INC. | $23.27 | 2022 | |
| Acella Pharmaceuticals, LLC | $18.16 | 2025 | NP Thyroid 60 |
| Horizon Therapeutics Plc | $17.60 | 2022 | |
| Amneal Pharmaceuticals LLC | $17.52 | 2025 | Unithroid |
| Ibsa Pharma INC. | $17.30 | 2024 | Tirosint, Licart |
| Recordati_rare_diseases_inc. | $17.01 | 2022 | |
| Eusa Pharma (US) LLC | $17.01 | 2022 | |
| Almatica Pharma LLC | $16.28 | 2024 | Teriparatide |
| Senseonics, Incorporated | $16.00 | 2019 | |
| Xeris Pharmaceuticals, INC. | $14.13 | 2024 | Recorlev |
| Alexion Pharmaceuticals, INC. | $13.83 | 2020 | |
| Glaxosmithkline, LLC. | $12.43 | 2020 | |
| Sanofi Pasteur INC. | $12.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Igor Priven listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.